Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 156,590 shares, a growth of 646.3% from the July 30th total of 20,981 shares. Approximately 6.0% of the shares of the stock are sold short. Based on an average daily volume of 1,559,990 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC lifted its position in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the SEC. 34.30% of the stock is owned by institutional investors.

Bone Biologics Stock Down 0.5%

BBLG opened at $0.60 on Wednesday. The firm has a market capitalization of $1.67 million, a P/E ratio of -0.44 and a beta of 0.92. The stock has a fifty day moving average of $1.09 and a 200-day moving average of $1.20. Bone Biologics has a 12-month low of $0.58 and a 12-month high of $4.13.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). On average, analysts expect that Bone Biologics will post -1.23 earnings per share for the current fiscal year.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.